Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK510 in Advanced Osteosarcoma and Soft Tissue Sarcoma
NCT06117878Phase 1Recruiting
- Sponsor
- Base Therapeutics
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK510 in osteosarcoma (OS) and soft tissue sarcoma (STS) (4 arms), sponsored by Base Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 6 weeks and Maximum Tolerated Dose at 6 weeks. Started Sep 2022; status: recruiting.
02
Drugs
NK510
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06117878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06117878.